These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 24585268)

  • 1. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
    Sjouke B; Kusters DM; Kindt I; Besseling J; Defesche JC; Sijbrands EJ; Roeters van Lennep JE; Stalenhoef AF; Wiegman A; de Graaf J; Fouchier SW; Kastelein JJ; Hovingh GK
    Eur Heart J; 2015 Mar; 36(9):560-5. PubMed ID: 24585268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
    Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
    Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease.
    Sjouke B; Defesche JC; Hartgers ML; Wiegman A; Roeters van Lennep JE; Kastelein JJ; Hovingh GK
    J Clin Lipidol; 2016; 10(6):1462-1469. PubMed ID: 27919364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
    Sjouke B; Hovingh GK; Kastelein JJ; Stefanutti C
    Curr Opin Lipidol; 2015 Jun; 26(3):200-9. PubMed ID: 25950706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family.
    Garcia-Garcia AB; Ivorra C; Martinez-Hervas S; Blesa S; Fuentes MJ; Puig O; Martín-de-Llano JJ; Carmena R; Real JT; Chaves FJ
    Atherosclerosis; 2011 Oct; 218(2):423-30. PubMed ID: 21868016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
    Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
    Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
    Sjouke B; Yahya R; Tanck MWT; Defesche JC; de Graaf J; Wiegman A; Kastelein JJP; Mulder MT; Hovingh GK; Roeters van Lennep JE
    J Clin Lipidol; 2017; 11(2):507-514. PubMed ID: 28502508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Durst R; Ibe UK; Shpitzen S; Schurr D; Eliav O; Futema M; Whittall R; Szalat A; Meiner V; Knobler H; Gavish D; Henkin Y; Ellis A; Rubinstein A; Harats D; Bitzur R; Hershkovitz B; Humphries SE; Leitersdorf E
    Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
    Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A
    Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.
    Bertolini S; Pisciotta L; Rabacchi C; Cefalù AB; Noto D; Fasano T; Signori A; Fresa R; Averna M; Calandra S
    Atherosclerosis; 2013 Apr; 227(2):342-8. PubMed ID: 23375686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of familial hypercholesterolemia in Spain.
    Palacios L; Grandoso L; Cuevas N; Olano-Martín E; Martinez A; Tejedor D; Stef M
    Atherosclerosis; 2012 Mar; 221(1):137-42. PubMed ID: 22244043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.
    Radovica-Spalvina I; Latkovskis G; Silamikelis I; Fridmanis D; Elbere I; Ventins K; Ozola G; Erglis A; Klovins J
    BMC Med Genet; 2015 Sep; 16():86. PubMed ID: 26415676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.
    Huijgen R; Sjouke B; Vis K; de Randamie JS; Defesche JC; Kastelein JJ; Hovingh GK; Fouchier SW
    Hum Mutat; 2012 Feb; 33(2):448-55. PubMed ID: 22095935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.